Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells
Andrew Sulaiman(University of Ottawa), Lisheng Wang(University of Ottawa), Guang Ji(Nantong University), Haiyan Song(Jiangxi Agricultural University), Zemin Yao(University of Ottawa), Angel Arnaout(Ontario Institute for Cancer Research), Christina Addison(Ontario Institute for Cancer Research), Sara El‐Sahli(University of Ottawa), Shelby Kaczmarek(University of Ottawa), Jim Dimitroulakos(Princess Margaret Cancer Centre), Jason Chambers(University of Ottawa), Suresh Gadde(University of Ottawa), Sarah McGarry, Sheng Liu(Yuhuangding Hospital), Li Li(Shanghai Jiao Tong University), Ying Xie(The First Hospital of Kunming), Xuguang Li(Health Canada), Carolyn Nessim(University of Ottawa), Ka Mien Lam(University of Ottawa)
Cited by 46
Related Papers
Drug resistance and new therapies in colorectal cancer
|World Journal of Gastroenterology|2018|604
Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug
|Nature Communications|2015|435
Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle
|Science Translational Medicine|2015|333
Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group
|Annals of Surgical Oncology|2021|251
Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
|The Journal of Immunology|2013|210